Design, setting, and participants
psychosis
This is an open-label randomized prospective comparative cohort trial based on a pragmatic design (online Supplement Fig. S2) (Relton, Torgerson, O'Cathain, & Nicholl, Patients with remitted psychosis receiving regular treatment at the outpatient or daycare services of a university-affiliated teaching hospital were invited to participate in this study from August 2017 to September 2022. Patients eligible for this study yet declined to participate in the dose reduction trial were invited to receive prospective follow-up under treatment as usual. Ethical approval has been obtained from the Research Ethics Committee of the study hospital, (REC: 201703002RIND) and this study was registered at ClinicalTrials.gov (identifier: NCT03248180).